Latham & Watkins guides biotechnology and biopharma merger - ICLG
Why now
Thesis: Biotech M&A activity, narrow relevance
Catalyst to watch: Deal terms or competing bids
Main risk: Deal may not close
Why it matters
Biotech merger legal advisory; deal-specific, no broad sector read-through.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-24 14:37 UTC